Lung Cancer

Small-cell lung cancer patients with high tumor mutation burden treated with immunotherapy had greater objective response rate, progression-free survival, and overall survival compared with patients with medium or low tumor burden.

While the incidence of irAEs is relatively low, the absolute number of patients receiving immune checkpoint inhibitors is steadily increasing. Thus, it is likely that, with time, larger numbers of patients will develop irAEs, including pneumonitis.

The second-generation EGFR tyrosine kinase inhibitor dacomitinib significantly improved progression-free survival over gefitinib as a first-line therapy for EGFR–positive non–small-cell lung cancer, according to a randomized phase III trial.

Data presented at the ESMO 2017 Congress demonstrated that alectinib may have CNS benefit in patients with advanced ALK-positive NSCLC.

This video reviews long-term results of the NRG Oncology RTOG 0915 trial, a randomized phase II study that compared stereotactic body radiation therapy delivered in one fraction vs four fractions for stage I peripheral non–small-cell lung cancer patients with unresectable disease.

This video highlights studies on advanced lung cancer with practice-changing potential presented at the 2017 ASTRO Annual Meeting.

Undergoing SBRT prior to starting maintenance chemotherapy significantly improved progression-free survival in patients with limited metastatic non–small-cell lung cancer, according to the results of a phase II study presented at the ASTRO Annual Meeting.

A case study from the University of Colorado suggests that traditional gene testing for NSCLC patients may not be sufficient for detecting potential oncogenic drivers.

People living with HIV who adhere to antiretroviral therapy but still smoke cigarettes are substantially more likely to die from lung cancer than from AIDS-related causes, according to the results of a new study.

Supplementation with B vitamins was associated with an increased risk of lung cancer among men, though not among women, according to a new study.

The FDA has approved the first cancer therapy biosimilar in the United States, a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, including colorectal, lung, brain, kidney, and cervical cancers.

Circulating tumor cells isolated from early stages of lung cancer may be predictive of poor prognosis and could potentially be predictive biomarkers of disease recurrence.

A study comparing two options for follow-up protocol after complete lung cancer resection suggests that regular CT scans after resection may not be necessary, though there may be some benefits to these additional scans.

This video reviews the need for biomarkers and tools that could identify those at high risk of immune-related toxicities among patients undergoing immunotherapy treatment.

The programmed death 1 (PD-1) inhibitor pembrolizumab offers promising antitumor activity and a safety profile consistent with earlier research in heavily pretreated patients with programmed death ligand 1 (PD-L1)–expressing extensive-stage small-cell lung cancer, according to results of a phase I study.

ASCO is issuing a new clinical practice guideline that clarifies the role of immunotherapy in the treatment of patients with advanced non–small-cell lung cancer.

This video reviews the role of surgery in the management of patients with mesothelioma.

Increases in the TP53 mutation in African American men with tobacco-related cancers may be responsible for chemotherapy resistance and a poorer prognosis overall.

Osimertinib demonstrated clinically meaningful progression-free survival benefit in EGFR mutation–positive NSCLC compared with current standard of care.

Researchers in Spain discovered a strange side effect of PD-L1 immunotherapy in some NSCLC patients-hair repigmentation-that may be a good response marker for this treatment.

This video reviews the role of surgery in patients with stage III (N2) non–small-cell lung cancer, highlighting some of the challenges in studying these patients and the need for multidisciplinary patient evaluations.

Computed tomography (CT) screening for lung cancer could lead to increased rates of smoking cessation in a high-risk population, with this “teachable moment” extending even to those with negative scan results.

Five-year results of a single-institution study show that proton beam radiotherapy given concurrently with chemotherapy offers promising clinical outcomes with good toxicity results compared with historical data.

A phase III trial failed to demonstrate superiority of eribulin over treatment of physician’s choice in patients with heavily pretreated non–small-cell lung cancer.

This video reviews pseudoprogression in non–small-cell lung cancer, including the incidence of this phenomenon and treatment considerations when it arises.